Clinical Trials associated with Glycine,L-alanine,L-arginine,L-aspartic acid,L-cysteine hydrochloride monohydrate,L-histidine,L-methionine,L-phenylalanine,L-proline,L-serine,L-threonine,L-tryptophan,L-tyrosine,L-glutamic acid,L-lysine monohydrate,taurine

NCT06652698

/ Not yet recruitingNot ApplicableIIT

Early Supplementation for Cow's Milk Allergy Prevention in Breastfed Infants in Poland (ESCAPE-PL): a Protocol for Randomised Controlled Trial

Cow's milk allergy (CMA) is a common food allergy in infants and young children that can have a significant impact on the individual and their family due to dietary restrictions, risk of nutritional deficiencies, social limitations, and decreased quality of life. It also represents a financial burden for families and healthcare resources.
There is an ongoing debate about the significance of early exposure to cow's milk proteins within hours or days after birth and its relationship to the risk of developing CMA later in life. Current recommendations for early introduction of cow's milk proteins in infants who cannot be breastfed vary and are inconsistent due to a lack of clear evidence. This knowledge gap underscores the need for further research to provide a definitive understanding of the relationship between early exposure to cow's milk proteins and the development of CMA, which will ultimately inform evidence-based prevention strategies to improve the health and well-being of affected individuals and their families.
This trial aims to investigate whether early supplementation with various nutritional interventions (cow's milk formula [CMF], amino acids formula [AAF], donor human milk [DHM], or high-pressure processed "pascalized" donor human milk [DHM-P]) could serve as an effective strategy for the primary prevention of CMA in breastfed neonates.
This study is an open-label randomized, controlled, head-to-head trial with four parallel arms and allocation 1:1:1:1.

Start Date01 Jul 2025

Sponsor / Collaborator

Warszawski Uniwersytet Medyczny

[+1]

NCT06721026

/ Not yet recruitingNot ApplicableIIT

Re-evaluation of the Muscle-full Effect During Continuously Elevated Amino Acid Availability in Healthy Young Males

Muscle tissue consists of proteins. These proteins are built up of a collection of smaller building blocks: amino acids. When protein is consumed, it gets digested and absorbed into the blood. The body can use these amino acids, by taking them up from thecirculation. By consuming sufficient protein through our diet, we ensure that the body is provided with enough amino acids to enable muscle protein building. Sufficient muscle protein synthesis is important for maintaining muscle function and strength.
Previous research has shown that when 20 to 25g of protein is eaten, muscle protein synthesis is maximized. It is therefore recommended to eat 20g of protein per meal. However, it is currently unclear what happens to muscle protein synthesis rates if multiple meals are eaten. When multiple meals are consumed, amino acids appear in the circulation for prolonged period of time.
Theoretically, when there are a high amino acid concentrations in the blood, muscle protein synthesis rates will increase. Contrary to this theory, a study more than 20 years ago showed otherwise. It was observed that muscle protein synthesis rates are only elevated for2 hours afterwhich they decrease again. This phenomenon was referred to as the "muscle-full" effect. Because this phenomenon is in contrast with more previous studies, the objective is to replicate that study. This is important so that nutritional advice for healthy, but also clinical populations in the future can be improved.

Start Date01 Mar 2025

Sponsor / Collaborator-

NCT02953223

/ CompletedNot Applicable

A Study to Monitor the Use of an Amino Acid-Based Infant Formula

To assess the frequency and nature of adverse events in infants fed a free amino acid based infant formula.

Start Date01 Jan 2017

Sponsor / Collaborator

Société des Produits Nestlé SA

100 Clinical Results associated with Glycine,L-alanine,L-arginine,L-aspartic acid,L-cysteine hydrochloride monohydrate,L-histidine,L-methionine,L-phenylalanine,L-proline,L-serine,L-threonine,L-tryptophan,L-tyrosine,L-glutamic acid,L-lysine monohydrate,taurine

100 Translational Medicine associated with Glycine,L-alanine,L-arginine,L-aspartic acid,L-cysteine hydrochloride monohydrate,L-histidine,L-methionine,L-phenylalanine,L-proline,L-serine,L-threonine,L-tryptophan,L-tyrosine,L-glutamic acid,L-lysine monohydrate,taurine

100 Patents (Medical) associated with Glycine,L-alanine,L-arginine,L-aspartic acid,L-cysteine hydrochloride monohydrate,L-histidine,L-methionine,L-phenylalanine,L-proline,L-serine,L-threonine,L-tryptophan,L-tyrosine,L-glutamic acid,L-lysine monohydrate,taurine

561

Literatures (Medical) associated with Glycine,L-alanine,L-arginine,L-aspartic acid,L-cysteine hydrochloride monohydrate,L-histidine,L-methionine,L-phenylalanine,L-proline,L-serine,L-threonine,L-tryptophan,L-tyrosine,L-glutamic acid,L-lysine monohydrate,taurine

01 Nov 2025·METABOLISM-CLINICAL AND EXPERIMENTAL

Symphony of regulated cell death: Unveiling therapeutic horizons in sarcopenia

Review

Author: Zou, Mi ; Hao, Liang ; Zhang, Qianmingyue ; Yan, Xiaohua ; Chen, Shuanghong ; Peng, Jie ; Liu, Dongcan ; Gao, Yuan ; Fang, Ruiying

Sarcopenia is a progressive musculoskeletal condition associated with aging, marked by a decline in muscle mass, strength, and performance. This condition not only compromises functional independence in older individuals but also contributes to escalating healthcare and economic burdens. Although the underlying mechanisms are complex and multifaceted, recent discoveries have emphasized the regulatory influence of multiple forms of programmed cell death-including apoptosis, ferroptosis, necroptosis, and pyroptosis-on skeletal muscle degeneration. These cell death pathways contribute to key pathological features such as muscle fiber loss, proteostasis imbalance, neuromuscular dysfunction, mitochondrial deficits, and persistent inflammation. This review synthesizes current understanding of the molecular underpinnings of regulated cell death (RCD) in sarcopenia and discusses emerging therapeutic interventions aimed at modulating these pathways. These include pharmacological agents (e.g., ferroptosis inhibitors, polyphenols), structured exercise programs (notably resistance), targeted nutritional support (e.g., amino acids, vitamin D), cell-based therapies, and gene-targeted strategies. Despite growing evidence supporting RCD as a viable therapeutic target, the interplay among different cell death modalities and the translation of mechanistic insights into clinical practice remain insufficiently understood. Advancing sarcopenia treatment will require integrated multi-omics analyses, identification of predictive biomarkers, and rigorously designed clinical studies to support personalized and effective therapeutic approaches.

01 Oct 2025·ACS Applied Materials & Interfaces

A Comparative Study of the Impact of Chemical Debridement Products on the Proteomic Profile of the Salivary Pellicle and Cell Adhesion on OsseoSpeed Titanium Dental Implant Surfaces

Article

Author: Wang, Qiang ; Santacroce, Marco ; Thiede, Bernd ; Haugen, Håvard Jostein ; De Lauretis, Angela ; Linke, Dirk ; Ellingsen, Jan Eirik ; Ma, Qianli ; Lyngstadaas, Ståle Petter

Background and objectives: Dental implants are commonly used for tooth replacement, with excellent success rates over 10 years. However, exposure to oral cavity bacteria makes them susceptible to biofilm accumulation, which can lead to peri-implant diseases. The salivary pellicle, a protein-rich layer formed on implant surfaces, mediates bacterial adhesion and cell attachment. Effective decontamination is essential for managing bacterial infections, yet no consensus exists on the best chemical agent. Understanding how chemical agents affect the pellicle proteomic profile may guide the selection of optimal treatments. Methods: We investigate the impact of chemical decontamination agents on the salivary pellicle on OsseoSpeed-like titanium dental implant surfaces using a BCA assay and proteomics, and on cell adhesion using human gingival fibroblasts (HGF) and human bone marrow mesenchymal stem cells (hBMSC). We compare the effects of hydrogen peroxide (H₂O₂), Poloxamer 407 (P407), P407 + H₂O₂ and sodium hypochlorite + amino acids (NaOCl + AA) using the salivary pellicle and a clean titanium surface as controls. By quantifying and identifying proteins on titanium surfaces after decontamination, this study reveals how chemical agents affect the salivary pellicle. Results: All products reduced the total protein on the surfaces, with the P407 + H₂O₂ hydrogel demonstrating lower protein variety and superior effectiveness in preventing surface recontamination. Not all proteins were removed during decontamination procedures, and unique proteins were detected in each experimental condition, suggesting protein readsorption depends on surface chemistry. P407 + H₂O₂ shows the highest enrichment in integrin- and cadherin-binding proteins upon recontamination. P407 and P407 + H₂O₂ promoted HGFs and hBMSCs attachment. Conversely, NaOCl + AA and H₂O₂ showed lower HGFs and hBMSCs counts. Conclusion: The P407 + H₂O₂ hydrogel had the strongest decontamination effect and limited surface recontamination. Each chemical agent produced a distinct proteomic profile. P407 and P407 + H₂O₂ promoted initial cell adhesion.

02 Sep 2025·Journal of Wound Care

Efficacy and safety of a medical device based on hyaluronic acid and amino acids for the topical treatment of hard-to-heal skin ulcers: a pilot clinical trial

Article

Author: Cassino, Roberto ; Reggiardo, Giorgio ; Romanelli, Marco ; Saponati, Giorgio ; Michelucci, Alessandra

Objective::

Wound healing is a complex process involving haemostasis, inflammation, proliferation and remodelling. Dysregulation in any phase impairs healing. Hyaluronic acid (HA) and amino acids are essential in promoting tissue repair. This study evaluated a topical medical device containing HA and amino acids for its safety and efficacy in treating hard-to-heal (chronic) wounds.

Method::

This four-week, one-arm, two-centre pilot clinical study included patients with hard-to-heal wounds of various aetiologies. Wounds were classified by exudate level and amount of necrosis. Treatment with different vehicles (cream, gel or powder) was tailored based on wound characteristics. Wound size was measured at baseline and final visit, while symptom severity was tracked using the total symptom score (TSS). Investigator assessment and safety monitoring were also conducted.

Results::

A total of 60 patients were included in the study. Wound size reduced significantly across all groups, with an average reduction of 54%, and 41% of patients achieving complete healing. Symptom severity, as measured by TSS, showed a consistent and significant reduction. Clinical improvement was observed in 95% of patients and no serious adverse events were reported. The product demonstrated good safety and tolerability.

Conclusion::

In this study, the HA and amino acids product effectively reduced ulcer size, improved symptoms and promoted healing, demonstrating its efficacy in hard-to-heal wound management. The findings are clinically significant but limited by the absence of a control group and a short observation period. Further randomised controlled trials are required to confirm these results and explore broader clinical applications.

News (Medical) associated with Glycine,L-alanine,L-arginine,L-aspartic acid,L-cysteine hydrochloride monohydrate,L-histidine,L-methionine,L-phenylalanine,L-proline,L-serine,L-threonine,L-tryptophan,L-tyrosine,L-glutamic acid,L-lysine monohydrate,taurine

23 May 2025

·endpoints.news

CHMP clears path for GSK’s Blenrep relaunch, recommends four other drugs

GSK, Roche and SpringWorks Therapeutics were among those that secured a positive opinion for new drugs from the European Medicines Agency’s human medicines committee (CHMP) on Friday. The agency gave the go-ahead for five new medicines including GSK’s multiple myeloma therapy called Blenrep. GSK is continuing to make headway for its relaunch, with this positive opinion coming a month after UK regulators approved the drug. Blenrep was originally approved in 2020, but GSK had to pull the drug from the US, UK and European markets after failing a confirmatory study in 2022. The FDA is also reviewing Blenrep for re-approval with a PDUFA date set for July 23. Meanwhile, CHMP also gave its support for Roche’s Itovebi, a PI3K inhibitor, for patients with PIK3CA mutated, estrogen receptor-positive, HER2 negative, locally advanced or metastatic breast cancer. CHMP’s opinion was based on its Phase 3 INAVO120 data, which also supported the FDA’s approval in October last year. On Thursday, Roche revealed survival data for Itovebi showing that patients had a 33% reduction in the risk of death, with data to be presented at the American Society of Clinical Oncology that starts next week. SpringWorks’ drug Ezmekly also secured a positive opinion from the European regulators as a treatment of symptomatic, inoperable neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PN), a disorder that causes tumors to grow along nerves and skin. Other new medicine approval recommendations from CHMP were: CHMP also recommended the European Commission to approve four label expansions: The European regulators gave a negative opinion of 4SC’s drug Kinselby and FGK Representative Service’s atropine sulfate. Elsewhere, CHMP recommended the approval of two new biosimilars from Fresenius Kabi Deutschland and one from Sandoz, as well as a hybrid medicine from Neuraxpharm. Editor’s Note: This story was updated to correct SpringWorks’ drug Ezmekly has been recommended as treatment for symptomatic, inoperable neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PN), not neurofibromatosis type 1 as previously mentioned.

Drug ApprovalPhase 3Clinical ResultASCOAccelerated Approval

100 Deals associated with Glycine,L-alanine,L-arginine,L-aspartic acid,L-cysteine hydrochloride monohydrate,L-histidine,L-methionine,L-phenylalanine,L-proline,L-serine,L-threonine,L-tryptophan,L-tyrosine,L-glutamic acid,L-lysine monohydrate,taurine

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Maple Syrup Urine Disease	European Union	Recordati Rare Diseases	28 Jul 2025
Maple Syrup Urine Disease	Iceland	Recordati Rare Diseases	28 Jul 2025
Maple Syrup Urine Disease	Liechtenstein	Recordati Rare Diseases	28 Jul 2025
Maple Syrup Urine Disease	Norway	Recordati Rare Diseases	28 Jul 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Glycine,L-alanine,L-arginine,L-aspartic acid,L-cysteine hydrochloride monohydrate,L-histidine,L-methionine,L-phenylalanine,L-proline,L-serine,L-threonine,L-tryptophan,L-tyrosine,L-glutamic acid,L-lysine monohydrate,taurine

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation